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Abstract
The current methods of publishing chemical information in bioscience articles are analysed. Using 3 papers as use−cases, it
is  shown that conventional methods using human procedures,  including cut−and−paste are time−consuming and introduce
errors. The meaning of chemical terms and the identity of compounds is often ambiguous. valuable experimental data such
as spectra and computational results are almost always omitted. We describe an Open XML architecture at proof−of−con-
cept  which  addresses  these  concerns.  Compounds  are  identified  through  explicit  connection  tables  or  links  to  persistent
Open  resources  such  as  PubChem.  It  is  argued  that  if  publishers  adopt  these  tools  and  protocols,  then  the  quality  and
quantity of chemical information available to bioscientists will increase and the authors, publishers and readers will find the
process cost−effective.
B O D Y
Introduction
In a previous article[1] we have argued the value of extracting the chemical information in bioscientific research, transform-
ing  it  to  XML  and  redisseminating  it  openly.  The  present  article  expands  on  the  technical  and  cultural  infrastructure
required to support this. The technical aspects have been solved to proof−of−concept stage and we are starting to embark on
experiments in the social domain. In this we thank BMC for inviting us to submit this and we present a model here which
we believe could be attractive for bioscience publishers and their community.
We concentrate on the current publication of chemistry in bioscience. This includes:
1. mention of chemical compounds. 
2. details of synthesis (in vivo and in vitro) of compounds. 
3. proof of structure (spectra and analytical data). 
4. Methods and reagents in bioscience bio−protocols 
5. properties of compounds. 
6. reactions and their properties, both in enzymes and enzyme−free systems. 
This type of chemistry is very well understood and has a simple ontology which has not changed over decades[2]. Unlike
much  bioscience,  where  ontological  tools  are  an  essential  part  of  reconciling  the  domain−dependent  approaches,  much
chemistry has an implicitly agreed abstract description. The problems are primarily reconciling syntax and semantics. This
is because chemists use abbreviated and lazy methods of communicating data, relying on trained readers to add information
from  the  context.  We  have  reviewed  current  problems  of  machine−understanding  of  chemistry[3]  in  a  typical  chemistry
journal,  many of  which are  perpetuated by  the  graphical  orientation of  conventional  publishing houses.  Here  we take  the
view that a committed publishing house can create a cost−effective and human−tolerable system for authoring semantically
correct chemistry in (bio)scientific documents.
We know from experience that Utopian visions do not sell themselves. The enormous and accepted value of the sequence
and  structures  databases  arose  not  from  the  demands  of  individual  authors,  but  from  wider  communities  of  researchers,
funders, and learned societies. Even now the deposition of protein structure data, without which journals will not generally
accept a paper, is seen by some as a chore and at worst as the donation of information to competitors. Without that commit-
funders, and learned societies. Even now the deposition of protein structure data, without which journals will not generally
accept a paper, is seen by some as a chore and at worst as the donation of information to competitors. Without that commit-
ment and the resource, however, Structural Biology would not exist as a discipline. Here we present the following vision;
that aggregated "small−molecule" chemical information, if deposited at publication, aggregated and disseminated, would be
seen as worth paying the prices of inconvenience.
Generic Infrastructure
For this proposal we make some assumptions about the evolving informatics environment:
 · The costs of archiving and maintaining scientific information can be now very much lower than some of the more tradi-
tional approaches.  There will  always be areas (patents, safety, reference data) where intensive human effort is  required in
the curation of data and where comprehensiveness is critical. This argument will be strongly made by the current chemical
secondary publishers who show no signs of changing their business model. However bioscience has shown that informatics
research is willing to balance quantity and quality and accepts that data is always used under caveat emptor. 
 · Much data is now completely captured instrumentally and can, in principle, be transmitted without syntactic loss. Crystal-
lography has shown that experimental data (in the CIF format) can be directly submitted to the publisher. Moreover with the
development  of  expert  programs  it  is  possible  to  review  the  data  by  machine  and  that  this  leads  to  higher  quality  than
before. The global aggregation of current small−molecule crystal structures, without any secondary curators or publishers,
can now meet almost all the needs of the community. 
 ·  Most  current  publicly  funded  chemical  data  is  never  published;  loss  varies  between 80% (crystallography) and  99.9%.
Much of this is due to the lack of simple technical and cultural protocols, which we address later. 
 · The primary cost is human time. Storage and CPU costs are trivial (for our domain). We show how the measures here, if
adopted,  would  save  all  members  of  the  community  considerable  time.  They  would  also  lead  to  the  creation  of  greatly
enhanced information resources. 
 · A variety of repositories will become available. In some communities (e.g. Physics and Computer Science) self−archiving
of (p)reprints is universal but in others it is rare. Early adopters of Institutional repositories (IRs) are starting to mandate that
the  output  of  publicly  funded  scholarship is  reposited,  and  we infer  that,  perhaps  with sharing schemes,  this  will  become
quasi−mandatory. There is potential conflict with publishers’ licenses, which we address below. 
 ·  There  will  be  sufficient  publishers  in  bioscience  who  are  attracted  by  approaches  like  ours,  and  that  this  will  create  a
critical  mass.  The  benefits  will  be  interoperable  approaches  to  authoring  (at  present  the  technical  requirements  of  some
publishers are grotesque, i.e. hardcopy, strange formats, etc.).
 · Openness. Our approach does not require Open Access, but does require that chemical data are Open. 
 ·  Willingness for  bioscientists  to  take  a  lead  in  chemical  informatics.  Chemical  information sources  are  manually aggre-
gated and curated secondary publications whose philosophy has barely altered over 120 years. There is a large quasi−monop-
oly  of  a  small  number  of  large  organisations  who  have  no  interest  or  inclination  in  changing  their  business  models  or
adopting  the  vision  of  the  Semantic  Web.  These  new technologies,  however,  are  ideally  suited  to  our  model  and  require
only modest investment. 
 ·  Open or cheap tools for publishing structured documents (in XML) which can be customised for different domains. As
XML becomes  the  universal  technology  for  publication  and  interoperability,  the  community  has  access  to  them  and  will
become trained in their use. As Open source components become more widespread it becomes possible to envisage scien-
tific authoring tools which meet many requirements of the publication process. 
We look to bioscience to take a lead in helping realise the following vision. On the positive we now believe that there are
already  enough  Open  tools  and  Open  resources  which  with  communal  will  among  bioscience  authors  and  publishers  can
make the vision attractive and cost−effective.
2
Automatic capture of chemical information
Much  chemical  data  is  largely  context−free  in  that  it  can  be  understood  and  recreated  independently  of  the  location  or
motivation. The primary data model is over 120 years old and was developed by Beilstein in the 19th century and comprises
three  components:  the  chemical  compound,  its  properties  and  citations.  A  pure  compound  is  described  by  an  immutable
structural formula and has precisely reproducible properties. There are qualifications (e.g. some properties may depend on
the  precise  crystalline  form)  but  it  has  served  as  the  basis  of  a  multimillion chemical  information  market,  with  the  com-
pound  at  the  centre.  Current  thinking  asserts  that  the  biological  action  of  a  compound  is,  in  principle,  reproducible  and
predictable  if  the  system is  carefully  enough  replicated  and  the  components  understood.  This  is  the  central  dogma of  the
chemically−based pharmaceutical industry.
Chemistry has a tradition of quality through properties and analysis, so every new compound (and many resynthesised ones)
mentioned in the literature must be accompanied by measurements of properties to justify identity and purity. These facts
are available, in text form, in the primary literature in which over a million new compounds are published annually. Because
structure predicts properties, and because drug discovery is so difficult, the pharmaceutical industry tests many compounds
for biological activity. It is therefore the primary financial engine for the chemical information industry.
The components
Techniques for managing items 1−5 listed above such as aggregating chemical compounds, properties and for searching the
results, are very well understood and can be easily made nearly automatic. Most of the information of benefit to the commu-
nity  exists  on  the  authors’  computers  in  machine−processable  form.  It  can  be  automatically  converted  into  fine−grained
XML[4]  with  almost  no  loss.  The  chemist  has  electronic  copies  of  molecular  structures,  spectra  and  properties  whose
semantics are extremely well understood and where a simple technical protocol for conversion to XML and hence publica-
tion can be created. To support this part of the data publication process we have created the XML−based Chemical Markup
Language (CML)[5]. The primary information components (all of which are common and well understood) are:
 · Molecular structure. A compound is described by a compositional formula (e.g. CH3OH for methanol) and a graphical
structural formula ("2D diagram"). These descriptions are required in bioscience publications for new compounds or where
scientific  arguments  are  based  on  details  of  chemical  structure.  There  are  a  few  widely  used  standalone  tools  (mainly
commercial)  for  drawing  structures  and  calculating  certain  properties.  They  output  a  variety  of  machine−processable
formats (MDL Molfiles, ChemDraw CDX files, and increasingly CML). The main challenge is that the output is designed
for the sighted human reader and that semantics may be implicit, discussed below. The Open Source community is creating
tools (e.g. JChempaint[6]) that will be valuable in authoring publications.
 · Chemical entities and names. Many compounds have no explicit structures and are mentioned by names or identifiers.
Where  these  relate  to  specific  compounds  (rather  than  generic  such  as  "phenols")  it  is  valuable  to  link  them to  a  precise
identification.
 ·  Spectra.  Many  traditional  formats  (JCAMP  and  some  manufacturers)  are  satisfactorily  machine−processable,  and  we
expect the XML−based AnIML[7] to be widely adopted by manufacturers.
 ·  Crystal Structures. Relatively few small−molecule crystal  structures are  reported in bioscience publications, but when
they are we have a workflow−driven system that extracts the data automatically and reposits it 
 ·  Molecular  properties.  These  are  required  as  proof−of−synthesis  and  use  a  small  dictionary  of  properties[8].  Their
publication is highly ritualised and we expect that a publisher−wide template for the submission of this information would
be straightforward to compile and welcomed by many authors. 
Identifying compounds
The identification of chemical entities is the most valuable contribution that an author can make. In most cases s/he (as, say,
the  purchaser  or  creator  of  the  materials)  is  the  best  judge  of  what  was  used  .  It  is  more  considerably  more  difficult  to
identify compounds after publication as we show below.
We list possible methods of publishing the identity of compounds in machine−understandable form:
 · Connection table. This is the most powerful method and we urge that every report of a chemical synthesis be accompa-
nied by a connection table. It already exists in the authors’ laboratory (in MOL, Chemdraw, SMILES, and increasingly as
CML). It is rare that a pure molecule in the bioscience literature cannot be represented in this way. This is the single most
important recommendation in this manuscript. 
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 · Chemical structure diagram. This is a useful adjunct to a connection table (and some of the formats combine the two).
Very occasionally (e.g. for catenanes, helicenes) a diagram is essential, but it should never be used instead of a connection
table. 
 ·  InChI. For  most  compounds  of  bioscientific  interest  with known structure it  is  possible  to  generate  a  unique identifier
using  the  new  InChI  (International  Chemical   Identifier)[9]  from  IUPAC.  This  has  major  advantages  over  non−semantic
identifiers  and  Closed  proprietary  canonical  identifiers  such  as  SMILES[10].  In  principle  an  InChI  not  only  uniquely
identifies the substance but also contains all the essential structural information. InChI in its current version (1.0) (and often
other canonicalization schemes as well) has some significant limitations for systems with metal ions and ionic compounds, a
situation which apparently will  be addressed in a  future InChI revision.  Simple molecules such as  e.g.  cis−Platin are  cur-
rently  included  in  the  handling,  although  the  stereochemical  aspects  are  not  currently  captured.  Handling  such  aspects  of
e.g. metal−based drugs must clearly be a high priority in the development of InChI. 
 ·  Semantically free identifiers. These are provided by authorities (e.g. Chemical Abstracts, RTECS, PubChem, etc.).  To
be useful they should have an Open mechanism for their resolution (e.g. in PubChem), but this is often expressly forbidden.
Thus Chemical Abstracts[11] forbids the public exposure of more than 0.1% of its content. Unless persistent Open machine−
friendly resolution is  available  we deprecate  the  use  of  authority−controlled identifiers  as  unique  IDs in  primary publica-
tions. There are very few cases (e.g. zeolites) where identifiers are the best means of identification. 
 ·  Trivial  ("Common")  names.  The  structures  of  many  compounds  ("aspirin",  "testosterone",  "glycine"...)  can  only  be
found through lookup. In the past these names have been controlled in Closed collections but there are now an increasing
number of Open lexicons of names:structures. The NCI led the way (220,000 names for ca 50,000 structures) and PubChem
[12] has continued to develop this.  If  commercial suppliers make their  catalogs Open then most of the common chemical
names in scientific discourse can be automatically linked to connection tables. 
 ·  Systematic  chemical  names.  Until  now  this  has  been  a  common  means  of  transmitting  chemical  identity,  but  it  now
serves little purpose, although It may be required legally, e.g. for patents. Most chemists would prefer a structural diagram
to a systematic name, and many regard name generation as a tedious chore. In principle IUPAC[2] chemical names obey a
context−free grammar and there are complex rules for canonicalization. In practice most authors use a variety of shortcuts.
This means that most compounds are reported with a variety of near synonyms (thus "2−hydroxy−toluene", "2−methyl−phe-
nol" are semi−systematic variants for "1−hydroxy−2−methyl−benzene"). Free−text searching on chemical names has almost
always  low  precision  and  often  low  recall.  It  is  a  common  error  to  assume  that  deterministic  grammars  can  parse  any
chemical name; in practice typographical errors, elisions and trivial fragments lower precision considerably. Some commer-
cial  tools  are  available  but  their  algorithms are  closed and little research has  been done on their  precision and recall.  We
suspect that they are composed of lexicons and heuristics but have no information on how they are maintained, especially in
light of revisions of naming conventions. 
Issues with chemical names
Chemical  names  can  be  used  with  more  or  less  specificity.  Thus  "1,4−dichlorobenzene"  is  unambiguous  in  any  context.
However there are several areas where more generic language is used. This can arise because:
 ·  The name refers to a  class of  compounds,  whose members have similar structures and/or properties: "steroids", "amino
acids", "monosaccharides", "polychlorinated biphenyls". 
 · The substance is a mixture of compounds: "60−80 petrol", "xylenes", "the phospho−inositols" 
 · The substance has not been fully identified: "the estradiol monobenzoate was ..." (there are two possibilities) 
 · The stereochemistry is ambiguous. The possibilities (in decreasing order of merit) include: 
Stereochemistry is known and reported. 
Stereochemistry is unknown and reported as such. 
Stereochemistry is partially known and reported as such. 
Stereochemistry is not reported but is unknown 
Stereochemistry is not reported but is known 
Stereochemistry is partially reported but is completely known 
Stereochemistry is reported and is wrong 
"Glutamic  acid"  is  an  example  of  ambiguity  through  unspecified  stereochemistry.  Thus  PubChem lists  the  three  isomers
(Table 1).
A structure without any stereo information is more valuable than one with partial information of unknown quality. The InChI
[9] is an extremely powerful tool here. We have recently shown that "staurosporine" reported in publications and suppliers
catalogs contains many instances of incorrect stereochemistry, and some partially correct and incorrect. Given that this is a
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[9] is an extremely powerful tool here. We have recently shown that "staurosporine" reported in publications and suppliers
catalogs contains many instances of incorrect stereochemistry, and some partially correct and incorrect. Given that this is a
single  substance,  its  structure  and  absolute  configuration  has  been  known  for  a  considerable  time  there  is  no  reason  for
using any structure other than PubChem CID: 44259
 ·  Ionization.  Protons are  labile  in  aqueous  systems and (for  example)  aminoacids can have several  ionization states.  The
importance of ionization details varies; 
"Acetic acid (0.1M) was added..." [ionization state irrelevant] 
Acetic acid forms a hydrogen−bonded dimer in the crystal. [single species, determinable by crystallography] 
We  computed  the  structure  of  glycine  zwitterion acid  (NH3+CH2CO2  -)  in  the  gas−phase  [single  species,  distinct  from
NH2CH2CO2H] 
"Glutamic acid is the most common excitatory neurotransmitter in the CNS" [irrelevant in macroscopic experiment, critical
in modelling action at receptor] 
 ·  Tautomerism. Many  neutral  compounds,  particularly  with  heteroatoms have  mobile  hydrogens  in  solution.  Thus  2−hy-
droxy pyridine (see Figure 1) exists as both forms with very rapid interchange. PubChem (as with many other systems) lists
them as the same compound (CID8871) and gives the many synonyms including "2(1H)−Pyridinone" and "2−HYDROXY-
PYRIDINE". InChI[9] has an extensive system for detecting tautomerism in compounds with heteroatoms, but does not yet
address carbon compounds (e.g. CH2=CHOH as a tautomer of ethanal (acetaldehyde, CH3−CH=O). 
 · Imprecise or polysystemic use. This often occurs when a chemical entity is incorporated into a larger system 
"This polysaccharide has a high mannose content" means "... contains many mannosyl fragments ..." 
"HIV protease has a catalytic aspartic acid..." means "... an aspartyl residue ..." 
The  preceeding  discussion  shows  how  ambiguity  and  loss  of  information  can  occur  if  structured  procedures  are  not  fol-
lowed. The  examples in Table 2 show some suggested approaches to markup which can re−capture much of the informa-
tion loss described above. The last example references a generic name, monosaccharide, in the IUPAC guide[2] to organic
nomenclature with a suggested use of identifiers.
Case studies
In this second section, we take 3 articles from BMC publications and show the success and problems of extracting chemis-
try in machine−understandable form. These have been randomly selected and do not necessarily reflect the average quality
of BMC publications. We note that in our other studies of chemical text very few publications were error−free.
Case Study 1: Identification of compounds in discourse and reagents in methods[13].
The abstract is typical of the discourse:
Background:  Recent  studies  indicate  that  the  G  protein−coupled  receptor  (GPCR)  signaling  machinery  can  serve  as  a
direct target of reactive oxygen species, including nitric oxide (NO) and S−nitrosothiols (RSNOs). To gain a broader view
into the  way that  receptor−dependent  G protein activation − an early  step in  signal  transduction − might be affected by
RSNOs, we have studied several receptors coupling to the Gi family of G proteins in their native cellular environment using
the powerful functional approach of [35S]GTPgammaS autoradiography with brain cryostat sections in combination with
classical G protein activation assays.
Results:  We  demonstrate  that  RSNOs,  like  S−nitrosoglutathione  (GSNO)  and  S−nitrosocysteine  (CysNO),  can  modulate
GPCR signaling via reversible, thiol−sensitive mechanisms probably involving S−nitrosylation. RSNOs are capable of very
targeted regulation, as  they potentiate the signaling of  some receptors (exemplified by the M2/M4 muscarinic cholinergic
receptors),  inhibit  others  (P2Y12 purinergic,  LPA1lysophosphatidic acid,  and  cannabinoid  CB1 receptors),  but  may  only
marginally  affect  signaling  of  others,  such  as  adenosine  A1,  µ−opioid,  and  opiate  related  receptors.  Amplification  of
M2/M4 muscarinic responses is explained by an accelerated rate of guanine nucleotide exchange, as well as an increased
number  of  high−affinity  [35S]GTP?S binding  sites  available  for  the  agonist−activated  receptor.  GSNO amplified  human
M4 receptor signaling also under heterologous expression in CHO cells, but the effect diminished with increasing constitu-
tive receptor activity. RSNOs markedly inhibited P2Y12 receptor signaling in native tissues (rat brain and human platelets),
but failed to affect human P2Y12 receptor signaling under heterologous expression in CHO cells, indicating that the native
cellular signaling partners, rather than the P2Y12 receptor protein, act as a molecular target for this action.
Conclusion: These in vitro studies show for the first time in a broader general context that RSNOs are capable of modulat-
ing GPCR signaling in a reversible and highly receptor−specific manner. Given that the enzymatic machinery responsible
for  endogenous  NO  production  is  located  in  close  proximity  with  the  GPCR  signaling  complex,  especially  with  that  for
several  receptors  whose  signaling  is  shown  here  to  be  modulated  by  exogenous  RSNOs,  our  data  suggest  that  GPCR
signaling in vivo is likely to be subject to substantial, and highly receptor−specific modulation by NO−derived RSNOs. 
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Conclusion: These in vitro studies show for the first time in a broader general context that RSNOs are capable of modulat-
ing GPCR signaling in a reversible and highly receptor−specific manner. Given that the enzymatic machinery responsible
for  endogenous  NO  production  is  located  in  close  proximity  with  the  GPCR  signaling  complex,  especially  with  that  for
several  receptors  whose  signaling  is  shown  here  to  be  modulated  by  exogenous  RSNOs,  our  data  suggest  that  GPCR
signaling in vivo is likely to be subject to substantial, and highly receptor−specific modulation by NO−derived RSNOs. 
The above contains reference to a considerable numbers of individual compounds. The authors helpfully publish a table of
abbreviations  to  assist  in  the  compound  identification  process  (Figure  2).  Using  this  as  our  data,  we  have  attempted  to
identify (Table 3) the "small−molecules" mentioned in the discourse. Using PubChem and occasional suppliers catalogs, the
elapsed real time was about 1 hour. It can be seen that of 19 molecules, 15 were identified without problems or error, 2 were
not  (CysNOGly  and  Glu−CysNO)  and  2  required  additional  expertise  by  the  reader.  We  estimate  that  it  would  take  an
author the same amount of time to add PubChem IDs for novel compounds and much less time if they were in common use
in their laboratory.
It is only a little additional effort to convert each molecule to a more formal description expressed in e.g. CML[5] and which
can carry not only an atom connection table and the corresponding InChI identifer, but also molecule "meta−data" describ-
ing the provenance of the information:
<cml:molecule xmlns:cml="http://www.xml−cml.org/schema/cml2/core" 
title="carbacholine">
<cml:metadataList title="generated automatically from Openbabel">
<cml:metadata name="dc:creator" content="OpenBabel version 1−100.1"/>
<cml:metadata name="dc:description" content="Conversion of legacy filetype to 
CML"/>
<cml:metadata name="dc:identifier" content="InChI"/>
<cml:metadata name="dc:content"/>
<cml:metadata name="dc:rights" content="open"/>
<cml:metadata name="dc:type" content="chemistry"/>
<cml:metadata name="dc:contributor" content="rzepa"/>
<cml:metadata name="dc:creator" content="Openbabel V1−100.1"/>
<cml:metadata name="dc:date" content="Tue May 17 12:02:50 BST 2005"/>
<cml:metadata name="cmlm:structure" content="yes"/>
</cml:metadataList>
<cml:identifier convention="iupac:inchi">InChI=1/C6H14N2O2.ClH/c1−8(2,3)4−5−10−
6(7)9;/h4−5H2,1−3H3,(H−,7,9);1H</cml:identifier>
<cml:atomArray atomID="a1 a2 a3 a4 a5 a6 a7 a8 a9 a10 a11 a12 a13" 
     elementType="N C C O C O N C C C H H Cl" 
     formalCharge="1 0 0 0 0 0 0 0 0 0 0 0 −1" 
     x2="−1.892900 −1.178500 −0.464000 0.250500 0.964900 0.964900  1.761800 
−2.305400 −2.476300 −1.480400 2.174300 2.476300 −1.921800" 
     y2="0.415300 0.827800 0.415300 0.827800 0.415300 −0.409700 0.628800 1.129800 
−0.168000 −0.299200 1.343300 0.216300 −1.343300"/>
<cml:bondArray atomRef1="a1 a1 a1 a1 a2 a3 a4 a5 a5 a7 a7" 
               atomRef2="a2 a8 a9 a10 a3 a4 a5 a6 a7 a11 a12" 
               order="1 1 1 1 1 1 1 2 1 1 1"/>
</cml:molecule>
Such molecular  datuments can be  embedded in  any XML−based document  in  a  manner  which can if  needed survive e.g.
journal production processes, and where the molecular information can be extracted and re−used at any stage. 
Case Study 2: Identity and properties of synthesised compounds[14]
Our critique of the chemistry requires context, given by the abstract:
Abstract Background: Kynureninase is a key enzyme on the kynurenine pathway of tryptophan metabo-
lism. One of the end products of the pathway is the neurotoxin quinolinic acid which appears to be 
responsible for neuronal cell death in a number of important neurological diseases. This makes 
kynureninase a possible therapeutic target for diseases such as Huntington’s, Alzheimer’s and AIDS 
related dementia, and the development of potent inhibitors an important research aim.
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Results: Two new kynurenine analogues, 3−hydroxydesaminokynurenine and 3− methoxydesami-
nokynurenine, were synthesised as inhibitors of kynureninase and tested on the tryptophan−induced 
bacterial enzyme from Pseudomonas fluorescens, the recombinant human enzyme and the rat hepatic 
enzyme. They were found to be mixed inhibitors of all three enzymes displaying both competitive and 
non competitive inhibition. The 3−hydroxy derivative gave low Ki values of 5, 40 and 100 nM respec-
tively. [...]
Conclusion: For kynureninase from all three species the 2−amino group was found to be crucial for 
activity whilst the 3−hydroxyl group played a fundamental role in binding at the active site presum-
ably via hydrogen bonding. The potency of the various inhibitors was found to be species specific. The 
3−hydroxylated inhibitor had a greater affinity for the human enzyme, consistent with its specificity 
for 3−hydroxykynurenine as substrate, whilst the methoxylated version yielded no significant differ-
ence between bacterial and human kynureninase. [...] 
We note that "quinolinic acid" has four mentions in the text, but its formula is not given. We took roughly three  minutes to
identify CID1066 in PubChem, with the additional useful information (from Medline/MeSH):
A metabolite of tryptophan with a possible role in neurodegenerative disorders. Elevated CSF levels 
of quinolinic acid are correlated with the severity of neuropsychological deficits in patients who have 
AIDS 
The name "3−hydroxydesaminokynurenine" [the synthesized compound (4) presents a more serious problem. Although the
structure is given in a diagram, the stereogenic centre is not marked. It would be a reasonable assumption that "kynurenine"
refers to a natural product which is only found in one enantiomeric form and "desamino" was also chiral. Careful reading
(requiring chemical expertise) showed that the authors had probably synthesised a racemic mixture, since they started with
achiral  compounds  and  did  not  report  chiral  reagents  or  a  resolution  step.  The  compound  should  have  been  reported  as
(R/S)−3−hydroxydesaminokynurenine or (much better) as the IUPAC−like name "IUPAC Name: (R/S) 2−amino−4−(3−hy-
droxy−phenyl)−4−oxo−butanoic  acid".  Indeed  many  referees  and  editors  would  have  insisted on  this  specification.  In  the
event, as we show below, this is not the reported compound!
The tools we are proposing would immediately have queried both these concerns at  time of authoring and,  had they been
available to the technical editor would have produced a more useful and more easily readable paper.
The  publication  of  the  synthesis  or  re−synthesis  of  compounds  must  be  accompanied  by  analytical  and  property  data  to
prove  purity  and  identitity.  The  ritualistic  presentation  shown below (Figure  3)  as  copied  from the  manuscript  is  entirely
typical of most chemical publications. Note that it is visually challenging to read and this is entirely due to the publisher’s
requirements of using a system designed to save paper rather than communicate useful information.
For each compound this compressed information is (manually) created from some or all of:
1. An elemental analysis (probably in machine−understandable form) 
2. A calculated composition for the compound (machine understandable) 
3. An infrared spectrum (machine understandable) 
4. A 1H NMR spectrum (machine understandable) 
5. A 13C NMR spectrum (machine understandable) 
6. A low resolution mass spectrum (machine understandable) 
7. A high resolution mass spectrum (machine understandable) 
For the publication, the authors have to measure peak heights from the spectrum (possibly with a ruler), and transcribe them
to a Word or PDF format, probably by typing the values or cut−n−pasting them. We have developed an Open Source robot
(OSCAR)[8] which can understand this data if it is syntactically correct, and the result is shown in Figure 4:
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The  coloured  parts  are  those  that  adhere  to  the  publication  guidelines.  We  found  7  changes  that  had  to  be  made  to  the
punctuation (missing punctuation,  syntactic  variation is  common in  many chemical  papers).  OSCAR can  then understand
and check the data. For compound [4] OSCAR produces the errror message:
There are fewer H atoms by NMR integration (7) than there are by 
elemental analysis (12)
This is acceptable because there are exchangeable groups. However OSCAR also gives the error flag:
There are more C−NMR environments (11) than there are C atoms from 
elemental analysis (10).
as it found the string "114.47 120.78". We also do not understand this and it may be an error (or it could be a solvent peak
or other impurity). OSCAR also had problems interpreting the chemical formula: "C11H14NO4" which in fact turns out to
be a charged species. In fact the compounds are poorly identified. They appear to be not the aminoacids "3−Hydroxydesami-
nokynurenine  (4)"  and  "3−Methoxydesaminokynurenine  (5)"  but  their  hydrochloride  salts.  This  is  not  a  trivial  error;  the
melting  points  and  infrared  spectra  of  the  parents  and  their  salts  will  be  significantly  different  and  would  cause  errors  if
transcribed unthinkingly from the paper.
Even with OSCAR it took one of us ca 45 minutes to make sure that the above analysis was correct. From several anecdotal
conversations with typical authors we estimate that it took about 2 hours to prepare this part of the submission; a thorough
reviewer might take 0.5 hour to decipher it. All of this is unnecessary if the original connection tables, spectra and analytical
data were made available in uncorrupted form. As it is, much of the original data is lost; using the reported peaks OSCAR
does its best to recreate what the spectrum might have looked like (Figure 5). Precise peak shapes and traces of impurities
are lost in this representation.
Case Study 3. Identity of compounds and preservation of calculations[15]
Here too a number of small−molecules are reported without formulae;
Background [...] Phenols and anilines are generally recognized as substrates of the heme peroxidases 
(donor: H2O2 oxidoreductases EC 1.11.17). The peroxidases catalyze oxidation of the substrates by 
hydrogen peroxide or alkyl peroxides, usually but not always, via free−radical intermediates [1,2]. 
Nonphenolic compounds, such as indole−3−acetic acid, phenylenediamines, ferrocenes, phenothiaz-
ines, phenoxazines, have also been investigated as peroxidase substrates [2][3−5]. Steady−state 
kinetics of peroxidase action has been described as a ping−pong scheme with compound I and com-
pound II formation [1]. 
This paper also has issues with the identity of compounds (Figure 6). This is again a visually unacceptable format dictated
by  the  prevailing  business  model  of  chemical  publishing.  Note  "Napthyl"  is  misspelt,  presumably  because  it  has  been
(mis)typed by the authors, which would give unnecessary problems to chemical text−mining robots. Worse, the identity of
AHA5 is  genuinely unclear,  in  that  the connection could be to either of  the phenyl  groups in the fragment: "Ph−C(O)N(-
OH)−Ph". BHA (also described elsewhere by "benzhydroxamic acid") has no structural or compositional formula. Worse,
BHA  in  the  PDB  ligand  collection  refers  to  2−hydroxy−4−amino−benzoic  acid  (a  completely  different  compound);
"benzhydroxamic acid" has code BHO.
Another  section  of  this  article  describes  various  computational  modelling  techniques  applied  to  these  molecules;  here  we
can  assume  that  the  authors  had  precise  coordinates  for  all  the  computed  species  available  at  the  end  of  the  research,
although  none  of  this  data  is  actually  made  available  via  the  final  published  article.  Some of  this  data  is  used  to  drive  a
docking program, which itself implies a protocol used to specify various run−time parameters. Some of these are declared in
the  article,  many  probably  default  to  values  set  internally  within  the  program.  There  are  also  ambiguities  in  the  declared
computational protocol:
The optimized geometry of molecules was used for energies and charges calculations with a 6−31G 
basis set using RHF and B3PW91 (Density Functional Theory). 
Here, the RHF and the B3PW91 protocols are mutually exclusive; either one or the other could have been used, but not in
combination. Mapping either protocol to e.g. the appropriate input for the program package used can also be a challenge for
anyone not totally familiar with the program; program manuals are still designed largely for human rather than machine use.
Such ambiguities, and lack of data, make repetition of the modelling more difficult for others.
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A Proposed infrastructure
It  should  now  be  clear  that  the  current  system  of  communicating  chemistry  (which  is  common  to  all  publishers  and  all
disciplines)  is  inefficient,  costly,  lossy,  and  of  questionable  quality.  We  present  a  new  XML−based  approach  which  we
show:
 · takes less time 
 · conveys more information
 · is easier to read 
 · allows published data to be aggregated and re−used 
We note that when starting to draft a publication the author already has
 · free text (A) (probably in handwritten form) 
 · properties (B) (probably handwritten form) 
 · spectra (C) (probably in digital form) 
 · molecules (D) (probably in MOL or ChemDraw files) 
Electronic lab notebook technology is  not  well  advanced in chemistry; our  architecture would provide a  good method for
preserving conventional data. It looks as shown in Figure 7 (blue = XML):
The  author  would  then  use  a  tool  which  can  manage  structured  XML  documents  and  provide  normal  textual  support
(spellchecks, etc.). There are 4 additional tools required to support chemical information:
 · A. Chemical lexical tool(AA) which can (a) parse free text(A) for possible compound names (b) look them up or (c) parse
them to create connection table and (d) insert a reference (AX) to the lexicon in the text, e.g.: 
... When foobarone is broken down, the presence of indole can be 
detected ...
might be marked up as
... When <cml:molecule name="foobarone" dictRef="natprod:foobarone"/> is broken 
down, the presence of <cml:molecule>
<identifier convention="iupac:inchi" title="indole">1/C8H7N/c1−2−4−8−7(3−1)5−6−9−
8/h1−6H,9H</identifier>
</cml:molecule>
indole can be detected ...
 · B. A controlled vocabulary (BB) of property types is used in a template to capture properties (B) and create a CML table
(BX), e.g. 
yield(93%), M.Pt. 273−275oC 
becomes 
<cml:list>
  <cml:property dictRef="cml:yield">
    <cml:scalar units="cml:percent">93%lt;/cml:scalar>
  </cml:property>
  <cml:property dictRef="cml:mpt">
    <cml:scalar units="cml:celsius" minValue="273" maxvalue="275"/>
  </cml:property>
</cml:list>
 · C. Spectra in legacy format (C) are automatically converted to CMLSpect or AniML (CX). 
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 · D. Molecules created in a conventional editor are either emitted in CML (DX) or automatically converted from legacy (D)
. 
The result is a single structured XML "datument"[16] containing fine−grained markup of facts (molecules, measurements,
properties,  chemical names).  This datument can be used to create derivatives such as  the "full−text" or  the "supplemental
data".  The complete datument (if  Open)  or  the  "data"  if  not  is  then reposited (XX)  where it  can  be  harvested.  New com-
pounds  with  their  names  are  fed  back  into  the  lexicon  and  all  compound/property  data  is  available  for  datamining  and
computational  re−use  (e.g.  for  further  in  silico  prediction.  A  human  or  robot  reader  has  access  to  the  same  lexicons  and
dictionaries  as  the  author  so  that  the  semantics  and  ontology  of  authoring  are  the  same  as  those  of  reading  (and  of
preservation).
Metadata and Rights
The social aspects of metadata and rights were addressed in (1). To meet these we place special emphasis on the XML and
its  metadata.  Fine−grained  XML  (e.g.  <scalar>...</scalar>  or  <molecule>...</molecule>  represents  facts  which  can  be
identified  as  Open  and  not  the  property  of  the  publisher.  Hyperlinks  and  structure  for  semantics  (e.g.  identification  of
compounds in PubChem) are also Open. Tools such as XSLT can then extract the factual, non−copyrightable information
with little technical  problem. Rights should be  explicitly marked up.  If  the publisher supports Open Access [17]  and also
Open Data then it is valuable to label the appropriate components with Open licenses, such as the RDF metadata provided
by Creative Commons. It is also possible to preserve authors’ moral rights and provenance of data re−used within the paper
(e.g. spectra of molecules or coordinates of protein structures).
Realising the vision
The transition to this architecture will have a cost, so short term−benefits are particularly attractive. Moreover most of the
parties are not used to a communal approach (pressures are normally per−institution and per−publisher).
Costs
 · Time lost in understanding and changing to a new system. 
 · New tools might cost money, or have to come from non−centralised budgets 
 · Only supported by a subset of publishers 
 · Communal deposition of data goes against the secretive culture 
 · Publishers have to invest in new system and react to community expectations 
Benefits
 · Open Access and Open Data[16] 
 · Greater quality in publications 
 · Data in theses and papers can be interchanged 
 · Greater readability, usability and innovation in publications 
 · Repository provides complete data record for laboratory, institution and world 
 · Modern informatics tools allow new types of search and aggregation 
 · Considerable time−savings during publication 
 · More efficient publishing reduces author frustration and time to publication 
 · and most importantly the arrival of the Scientific Semantic Web, allowing robots to read and take action on publications. 
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The benefits should also be clear for most individuals and organisations:
 · funders can ensure a much higher of dissemination of funded data will be available 
 · institutions mandate a greater proportion of funded science published; better visibility and preservation 
 · researchers spend less time on unproductive operations 
 · reviewers have easier access to background ontology of data in documents 
 · editors get greater automation 
 · publishers are relieved of need to archive supplemental data 
 · readers have information prosthetics for easier and faster reading 
 · librarians develop one of the best early repository applications in the digital age 
Potential
Because the chemical information is structured we now have a biocheminformatics cycle (this term − with spelling as here −
is in modest use. We suggest its adoption to describe the management of chemical information in biosciences and not just in
biochemistry) where, for the first time, large scale robotic data analysis can take place (Figure 8).
The data in the research (laboratory, in  silico,  or  both)  are  published in a  lossless manner.  Molecules and their  properties
have  unique  identifiers  as  described  above  and  can  be  integrated  into  mainstream  bioinformatics  in  the  same  manner  as
collections such  as  PubChem, MSDChem (at  EBI),  KEGG, etc.  They will  bring  the  added  value of  consistently captured
property data and spectra. We also expect that many in silico properties will then be systematically added.
Compliance and adoption
The  current  dissemination of  data  through  publishers  is  largely  unsatisfactory.  Some publishers,  such  as  the  International
Union  of  Crystallography,  see  it  as  core  business  and  others  in  the  biosciences  agree  to  link  to  international  databanks.
Many publishers allow the deposition of factual "supplementary data" but our experience with mainstream chemical publish-
ers is that it is an unwelcome chore, poorly resourced and maintained, and with virtually no quality control or curation over
the  content.  We  believe  that  many  publishers  would  welcome  a  model  where  they  were  no  longer  involved  in  data
repositing.
The introduction of structured authoring tools will help this process considerably. Templates can be created for the chemical
components described above and where the information exists in XML (connection tables, spectra, properties) it should be
as easy as for committed authors as using a semantically void tool (e.g. Word). Where information needs to be converted
from legacy  formats  we  have  created  Open  Web  Services  which  publishers  (and  authors)  may  clone  and  customise.  The
main technical challenge will be the management of chemical names in free text.
Conclusions and the future.
The  analysis  presented  here  introduces  the  basic  concepts  of  chemistry  in  bioinformatics.  Many  areas  remain  to  be
addressed; we briefly describe two below which have immediate application.
Reactions
Chemical reactions are very patchily abstracted from the literature and the products are almost always closed. The motiva-
tion for the primary publication of reactions in bioscience includes:
1. record of synthesis of compound and proof thereof 
2. record of an experimental protocol (e.g. biotinylation) 
3. record of a biochemical reaction, including xenobiotic processes 
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4. description of systems biochemistry (coupled reaction pathways) 
5. understanding of an enzyme mechanism 
CMLReact (an extension of CML) has been created[18] to support these catagories of reaction. Items 1−2 require identical
support as in mainstream chemistry (e.g. in journals supporting organic synthesis). Item 3 can be supported by CMLReact
though there is little current experience. Item 4 is supported by SBML[19] and efforts such as BioPAX[20] (in which CML
is a tool). Item 5 is particularly exciting and exemplified by our MACiE database where 150+ enzymes with 3D structures
and proposed mechanisms have been collected[21]. Currently the abstraction is manual and expensive, but if the ideas in the
current  paper  are  implemented  we  shall  present  an  extension  whereby  mechanisms  can  be  relatively  cheaply  captured  at
source. This would be a major new resource in bioinformatics.
Evaluation metrics
The  primary  motivation  for  a  publication,  of  course,  is  citability  and  the  technology  we  describe  raises  the  fear  among
chemists that the data in it might actually be read, analysed and re−used. However it also raises the vision of changing the
"citation economy" (which values market perception) to a "reuse economy" where the data in an article (or as we prefer, a
"datument") are valued by how often they are re−used.
Table 1. Isomers of Glutamic Acid
Name(s)
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
611 glutamic acid
33032 L−glutamic acid
23327 D−glutamic acid
Table 2. Examples of approaches to chemical Identification.
Prose description
More precise suggested naming 
using the CML[5] approach Type of information
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
Acetaldehyde has a general narcotic action
<p><cml:molecule> 
<cml:identifier 
convention="iupac:inchi">1/C2H4O/
c1−2−3/h2H,1H3</cml:identifier> 
<cml:identifier 
convention="pubchem:CID">177</cml
:identifier> </cml:molecule> has 
a ...</p> precise, redundant
Benzo(a)pyrene is a potent mutagen and 
carcinogen
<p><cml:molecule><cml:identifier 
convention="pubchem:CID">2336</cm
l:identifier></cml:molecule> is 
a ...</p>
precise
glycine (1mmol) was added ... <p><cml:molecule 
title="glycine"><cml:identifier 
convention="iupac:inchi">1/C2H5NO
2/c3−1−2(4)5/h1,3H2,(H,4,5)</cml:
identifier></cml:molecule> is a 
...</p>
hydrogens mobile
calculations on glycine zwitterion... <p><cml:molecule 
title="g><cml:identifier 
convention="pubchem:CID">InChI=1/
C2H5NO2/c3−1−2(4)5/h1H3,3H2</cml:
identifier></cml:molecule> is a 
...</p>
hydrogens precise
... a monosaccharide transporter... <p>a <cml:molecule 
title="monosaccharide"><cml:ident
ifier 
convention="iupac:carbohydrate">2
−Carb−2</cml:identifier></cml:mol
ecule> transporter ...</p>
Data
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Table 3. Identification of Small−molecules noted in Ref. 14
abbreviation author name PubChem ID Notes
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
2MeSADP 2−methylthio−ADP [121990]
Not found directly in PubChem. 
Located in supplier’s catalog. 
Synonym from that found in 
PubChem
5−HT 5−hydroxytryptamine 5202  
CCh carbacholine 521353  
CP−55940 (−)−3−[2−hydroxy−4−(1,1−dimeth
ylheptyl)−phenyl]−4−[3−hydroxyp
ropyl]cyclohexan−1−ol
104895 IUPAC: 5−(1,1−dimethylheptyl)−
2−[5−hydroxy−2−(3−hydroxyprop
yl)cyclohexyl]−phenol
CysNO S−nitrosocysteine 39933  
CysNOGly S−nitroso−cysteinyl−glycine  Text search on PubChem found 
wrong compound. Not found in 
major supplier
DAMGO [D−Ala2, N−Me−Phe4, Gly5−ol]−
enkephalin
104742  
DPCPX 8−cyclopentyl−1,3−dipropylxanthi
ne
1320  
Glu−CysNO L−?−glutamyl−S−nitrosocysteine  Identity unresolved
GSH glutathione 745  
GSNO S−nitrosoglutathione 104858  
LPA lysophosphatidic acid 3987  
NA noradrenaline 951 PubChem CID covers both 
racemic and d−enantiomer
NO nitric oxide 84878 PubChem also lists 945 (with 
incorrect formula HNO) as nitric 
oxide
NOBF4 nitrosodium tetrafluoroborate 151929 Paper has a typographical error 
for "nitrosonium". Structure in 
PubChem is wrong (formula 
should be NO+BF4-, not 
H2NO+.BF4-)
SNAP S−nitroso−N−acetyl−D,L−penicill
amine
5231 PubChem does not list 
stereochemistry
RSNO S−nitrosothiol  Appears to be a generic 
compound (R−S−N=O)
SNP sodium nitroprusside 26256  
    
Figure 1. Tautomers of Hydroxypyridine
Figure 1
Figure 2. Abbreviations used in reference 13.
Figure  2
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Figure 3. A linear text−based description of experimental detail and data taken from Ref. 14.
Figure 3
Figure 4. OSCAR output from the text−based description in Ref 14.
Figure  4
Figure 5. OSCAR generated spectrum of analytical information reported in Ref 14.
Figure 5
Figure 6. Structure diagram reported in Ref 15.
Figure  6
Figure 7. Data−flow illustrating the use of XML.
Figure 7
Figure 8. A Biocheminformatics Cycle.
Figure 8
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